Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells

Prostate cancer (PCa) represents the fifth cause of cancer death in men. Currently, chemotherapeutic agents for the treatment of cancers, including PCa, mainly inhibit tumor growth by apoptosis induction. However, defects in apoptotic cellular responses frequently lead to drug resistance, which is the main cause of chemotherapy failure. For this reason, trigger non-apoptotic cell death might represent an alternative approach to prevent drug resistance in cancer. Several agents, including natural compounds, have been shown to induce necroptosis in human cancer cells. In this study we evaluated the involvement of necroptosis in anticancer activity of delta-tocotrienol (δ-TT) in PCa cells (DU145 and PC3). Combination therapy is one tool used to overcome therapeutic resistance and drug toxicity. Evaluating the combined effect of δ-TT and docetaxel (DTX), we found that δ-TT potentiates DTX cytotoxicity in DU145 cells. Moreover, δ-TT induces cell death in DU145 cells that have developed DTX resistance (DU-DXR) activating necroptosis. Taken together, obtained data indicate the ability of δ-TT to induce necroptosis in both DU145, PC3 and DU-DXR cell lines. Furthermore, the ability of δ-TT to induce necroptotic cell death may represent a promising therapeutical approach to overcome DTX chemoresistance in PCa.

[1]  Hyung-Mun Yun,et al.  Latifolin, a Natural Flavonoid, Isolated from the Heartwood of Dalbergia odorifera Induces Bioactivities through Apoptosis, Autophagy, and Necroptosis in Human Oral Squamous Cell Carcinoma , 2022, International journal of molecular sciences.

[2]  N. Zaffaroni,et al.  Necroptosis and Prostate Cancer: Molecular Mechanisms and Therapeutic Potential , 2022, Cells.

[3]  B. Yousefi,et al.  The role of polyphenols in overcoming cancer drug resistance: a comprehensive review , 2022, Cellular & molecular biology letters.

[4]  F. Bray,et al.  Epidemiology and Prevention of Prostate Cancer. , 2021, European urology oncology.

[5]  M. Barakat,et al.  Targeting Drug Chemo-Resistance in Cancer Using Natural Products , 2021, Biomedicines.

[6]  N. Zaffaroni,et al.  δ‐Tocotrienol sensitizes and re‐sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK‐mediated apoptosis , 2021, Cell proliferation.

[7]  M. Ashrafizadeh,et al.  New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Yoon-Jin Lee,et al.  Curcumin Targets Both Apoptosis and Necroptosis in Acidity-Tolerant Prostate Carcinoma Cells , 2021, BioMed research international.

[9]  Sayeon Cho,et al.  The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance , 2021, Archives of Pharmacal Research.

[10]  Y. Assaraf,et al.  Therapeutic strategies to overcome taxane resistance in cancer. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  T. Efferth,et al.  Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis , 2021, Cancers.

[13]  S. Manickam,et al.  Stable W/O/W multiple nanoemulsion encapsulating natural tocotrienols and caffeic acid with cisplatin synergistically treated cancer cell lines (A549 and HEP G2) and reduced toxicity on normal cell line (HEK 293). , 2021, Materials science & engineering. C, Materials for biological applications.

[14]  Yoon-Jin Lee,et al.  Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells , 2020, Nutrition research and practice.

[15]  J. Teishima,et al.  Molecular mechanisms of docetaxel resistance in prostate cancer , 2020, Cancer drug resistance.

[16]  Subash C. Gupta,et al.  Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. , 2020, Seminars in cancer biology.

[17]  R. Mohammadinejad,et al.  Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects. , 2020, Life sciences.

[18]  Yihua Wang,et al.  The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistance , 2020, Cancer drug resistance.

[19]  K. Strebhardt,et al.  Caspase-8: The double-edged sword. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[20]  D. Michaelis,et al.  γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells , 2020, Molecules.

[21]  W. Stone,et al.  Upregulation of pERK and c-JUN by γ-tocotrienol and not α-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells , 2019, BMC Cancer.

[22]  M. Nieto,et al.  A gene regulatory network to control EMT programs in development and disease , 2019, Nature Communications.

[23]  Wei Zhang,et al.  Celastrol Induces Necroptosis and Ameliorates Inflammation via Targeting Biglycan in Human Gastric Carcinoma , 2019, International journal of molecular sciences.

[24]  R. Banjerdpongchai,et al.  Goniothalamin Induces Necroptosis and Anoikis in Human Invasive Breast Cancer MDA-MB-231 Cells , 2019, International journal of molecular sciences.

[25]  N. Luo,et al.  Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells , 2019, Biological Research.

[26]  Chao Yang,et al.  The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.

[27]  J. Clements,et al.  Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway , 2019, International journal of molecular sciences.

[28]  X. Tian,et al.  Bufalin engages in RIP1-dependent and ROS-dependent programmed necroptosis in breast cancer cells by targeting the RIP1/RIP3/PGAM5 pathway. , 2019, Anti-cancer drugs.

[29]  P. Limonta,et al.  δ‐Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells , 2019, Cell proliferation.

[30]  G. Sethi,et al.  Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements , 2019, International journal of molecular sciences.

[31]  Chaoyue Sun,et al.  Phytochemicals: Current strategy to sensitize cancer cells to cisplatin. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  P. Limonta,et al.  Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents. , 2019, Recent patents on anti-cancer drug discovery.

[33]  H. Loh,et al.  Tocotrienols Modulate a Life or Death Decision in Cancers , 2019, International journal of molecular sciences.

[34]  P. Limonta,et al.  Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets , 2018, Journal of cellular physiology.

[35]  A. Ceribelli,et al.  Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC , 2018, AntiCancer Research.

[36]  R. DePinho,et al.  Genetics and biology of prostate cancer , 2018, Genes & development.

[37]  Fabrizio Fontana,et al.  Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells , 2018, Cell Death & Disease.

[38]  P. Limonta,et al.  Semi-preparative HPLC purification of δ-tocotrienol (δ-T3) from Elaeis guineensis Jacq. and Bixa orellana L. and evaluation of its in vitro anticancer activity in human A375 melanoma cells , 2018, Natural product research.

[39]  Wei Li,et al.  Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies , 2018, Acta pharmaceutica Sinica. B.

[40]  A. Qureshi,et al.  Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs , 2018, Lipids in Health and Disease.

[41]  A. Kunnumakkara,et al.  Tocotrienols: The promising analogues of vitamin E for cancer therapeutics , 2018, Pharmacological research.

[42]  N. Kyprianou,et al.  Profiling Prostate Cancer Therapeutic Resistance , 2018, International journal of molecular sciences.

[43]  R. Kaur,et al.  Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer , 2017, British Journal of Cancer.

[44]  T. Yano,et al.  Combination Effect of δ-Tocotrienol and γ-Tocopherol on Prostate Cancer Cell Growth. , 2017, Journal of nutritional science and vitaminology.

[45]  J. Yustein,et al.  International Journal of Molecular Sciences Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue , 2022 .

[46]  P. Kantoff,et al.  Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression , 2016, Proceedings of the National Academy of Sciences.

[47]  H. Klocker,et al.  Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer , 2015, Oncotarget.

[48]  T. Yano,et al.  Annatto Tocotrienol Induces a Cytotoxic Effect on Human Prostate Cancer PC3 Cells via the Simultaneous Inhibition of Src and Stat3. , 2015, Journal of nutritional science and vitaminology.

[49]  J. Fitzpatrick,et al.  Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. , 2014, European urology.

[50]  A. A. Martens,et al.  The multiple facets of drug resistance: one history, different approaches , 2014, Journal of experimental & clinical cancer research : CR.

[51]  F. Rizzi,et al.  Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. , 2014, Carcinogenesis.

[52]  E. Gallardo,et al.  Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[53]  D. Zuo,et al.  The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis , 2013, BMC Cancer.

[54]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[55]  M. Azuma,et al.  γ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products , 2012, International journal of oncology.

[56]  D. Green,et al.  RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. , 2011, Molecular cell.

[57]  Y. Yap,et al.  Gamma‐tocotrienol as an effective agent in targeting prostate cancer stem cell‐like population , 2010, International journal of cancer.

[58]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[59]  Y. Imai,et al.  A mutation in β‐tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel‐resistant prostate cancer cell line , 2010, Cell biology international.

[60]  I. Tannock,et al.  Chemotherapy for patients with hormone-refractory prostate cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[62]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.